Rana Samadfam Headshot

Rana Samadfam, PhD, DABT, MSc

Scientific Director, In Vivo Pharmacology

Rana Samadfam received both an MSc and PhD in pharmacology from the Université de Sherbrooke. Following her postdoctoral training at McGill University, Rana joined Charles River, where she and her team focus on inflammation, immunology, autoimmune, IBD, respiratory, skin, and joint diseases. She is the recipient of several scientific awards, author of over 105 peer-reviewed publications, and editor of a bone toxicology book. Her articles have appeared in Scientific American, and her most recent peer-reviewed studies have been published in Journal of Bone and Mineral Research and Bone. Dr. Samadfam is a Diplomate of the American Board of Toxicology. 

LinkedIn: https://www.linkedin.com/in/rana-samadfam-phd-dabt-8a38a72



  • Pennypacker BL, Gilberto D, Gatto NT, Samadfam R, Smith SY, Kimmel DB, Duong le T. Odanacatib increases mineralized callus during fracture healing in a rabbit ulnar osteotomy model. J Orthop Res. 2016 Jan
  • Duong LT, Pickarski M, Cusick T, Chen CM, Zhuo Y, Scott K, Samadfam R, Smith SY, Pennypacker BL. Effects of long term treatment with high doses of odanacatib on bone mass, bone strength, and remodeling/modeling in newly ovariectomized monkeys. Bone. 2016 Jul
  • Chouinard L, Felx M, Mellal N, Varela A, Mann P, Jolette J, Samadfam R, Smith SY, Locher K, Buntich S, Ominsky MS, Pyrah I, Boyce RW. Carcinogenicity risk assessment of romosozumab: A review of scientific weight-of-evidence and findings in a rat lifetime pharmacology study. Regul Toxicol Pharmaco; 2016 Nov
  • Smith SY, Samadfam R, Chouinard L, Awori M, Bénardeau A, Bauss F, Guldberg RE, Sebokova E, Wright MB. Effects of pioglitazone and fenofibrate co-administration on bone biomechanics and histomorphometry in ovariectomized rats.J Bone Miner Metab. 2015 Nov;33(6):625-41.
  • S Takeda, SY Smith, T Tamura, H Saito, F Takahashi, R Samadfam, S Haile, N Doyle, K Endo, Long-Term Treatment with Eldecalcitol (1α, 25-Dihydroxy-2β-(3-hydroxypropyloxy) Vitamin D3) Suppresses Bone Turnoverand Leads to Prevention of Bone Loss and Bone Fragilityin Ovariectomized Rats, Calcif Tissue Int, 2014
  • PJ. Kostenuik, SY Smith, R Samadfam, J Jolette, L Zhou, and Ml Ominsky, Effects of Denosumab, Alendronate, or Denosumab Following Alendronate on Bone Turnover, Calcium Homeostasis, Bone Mass and Bone Strength in Ovariectomized Cynomolgus Monkeys, 2014, JBMR in press
  • SY Smith, R Samadfam, L Chouinard, M Awori, A Bénardeau, F Bauss, RE Guldberg, E Sebokova, and MB Wright. Effects of pioglitazone and fenofibrate co-administration on bone biomechanics and histomorphometry in ovariectomized rats. JBMMA 2014 (in press).
  • BL Pennypacker, CM Chen, H Zheng, M-S Shih, M Belfast, R Samadfam, LT Duong , Inhibition of Cathepsin K Increases Modeling-Based Bone Formation, and Improves Cortical Dimension and Strength in Adult Ovariectomized Monkeys. JBMR, Aug;29(8):1847-58, 2014
  • MA Gentile, DY. Soung, C Horrell, R Samadfam, H Drissi, LT Duong, Increased fracture callus mineralization and strength in cathepsin K knockout mice, Bone. 2014 Sep;66:72-81.
  • L Pouliot, M Schneider, M DeCristofaro, R Samadfam, SY Smith, and DA Beckman. Assessment of a nonsteroidal aromatase inhibitor, letrozole, in juvenile rats. Birth Defects Research (Part B) 98:374–390 (2013)
  • S Kumar, SJ Hoffman, R Samadfam, P Mansell, J Jolette, SY Smith, RE Guldberg, LA Fitzpatrick. The effect of rosiglitazone on bone mass and fragility is reversible and can be attenuated with alendronate. J Bone Miner Res. 2013 Jul;28(7):1653-65.
  • R Samadfam, M Awori, A Benardeau, F Bauss, E Sebokova, M Wright, SY Smith, Combination treatment with pioglitazone and fenofibrate attenuates pioglitazone-mediated acceleration of bone loss in ovaroectimized rats, Journal of Endocrinology, 2012 Feb;212(2):179-86
  • PJ Masarachia, BL Pennypacker, M Pickarski, KR Scott, GA Wesolowski, SY Smith, R Samadfam, JE Geotzmann, BB Scott, DB Kimmel, and LT Duong, Odanacatib reduces bone turnover and increases bone mass in th4e lumbar spine of skeletally mature ovariectomized rhesus monkeys, JBMR, 2012 Mar;27(3):509-23
  • BS Komm, F Vlasseros, R Samadfam, L Chouinard, SY Smith, Skeletal Effects of Bazedoxifene Paired With Conjugated Estrogens in Ovariectomized Rats, Bone, 49:376-386, 2011
  • BL Pennypacker, LT Duong, TE Cusick, PJ Masarachia, MA Gentile, JY Gauthier, WC Black, BB Scott, R Samadfam, SY Smith, DB Kimmel. Cathepsin K inhibitors prevent bone loss in estrogen-deficient rabbits. J Bone Miner Res. 2010 Aug 23
  • M Ominsky, C Li, X Li, Hong L Tan, E Lee, M Barrero, F J Asuncion, D Dwyer, C-Y Han, F Vlasseros, R Samadfam, J Jolette, SY Smith, M Stolina, L William, S Simonet, C Paszty, G Li, HZ Ke. Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of non-fractured bones. J Bone Miner Res. May;26(5):1012-21, 2010
  • C Richard, D Miao, R Samadfam, Y Wang., GN Hendy, D Goltzman. (2009) Deletion of the 25 Hydroxy Vitamin D 1α Hydroxylase from Mice Expressing the Null Mutation for the Calcium Sensing Receptor Converts a Hypercalcemic to a Hypocalcemic Hyperparathyroid Phenotype. JBMR, Vol. 25, No. 7, July 2010, pp 1627–1636.
  • R Samadfam, C Richard, L Nyugen-Yamamoto, I Bolivar, and D Goltzman (2009) Bone Formation Regulates Circulating Concentrations of FGF23 and involves the Action of Dentin Matrix Protein1. Endocrinology, Nov;150(11):4835-45
  • R Samadfam, D Miao, GN Hendy, D Goltzman. (2008) Exogenous PTH and endogenous 1,25-dihydroxyvitamin D are complementary in inducing an anabolic effect on bone. J Bone Miner Res. 2008 Aug;23(8):1257-66.
  • R Samadfam, Q Xia, and D Goltzman. (2007) Cotreatment of Parathyroid Hormone with Osteoprotegerin or Alendronate Increases its Anabolic Effect on the Skeleton of Oophorectomized Mice. J Bone Miner Res. 2007 Jan;22(1):55-63.
  • R Samadfam, Q Xia, and D Goltzman. (2007) Pretreatment with anticatabolic agents blunts but does not eliminate the skeletal anabolic response to parathyroid hormone in oophorectomized mice. Endocrinology. 2007 Jun;148(6):2778-87.
  • J Gao, Y Yang, R Samadfam, TP Rashmi, D Miao, AC Karaplis, M Ram Sairam, D Goltzman (2007) Altered ovarian function affects skeletal homeostasis independent of the action of follicle-stimulating hormone. Endocrinology. 2007 Jun;148(6):2613-21.
  • R Samadfam, M Gallant, MC Miousse, and AJ de Brum-Fernandes. (2006) Implication of prostaglandin receptor subtypes in expression in OPG in primary human osteoblasts and immortalized osteoblastic cell lines, Journal of Rheumatology, Jun;33(6):1167-75.
  • M Gallant. R Samadfam, and AJ de Brum-Fernandes (2005) Expression of CRTH2 in human osteoblasts. J. Bone Miner Res. 2005 Apr; 20 (4):672-81 I Fortier, C Patry, M Lora, R Samadfam, AJ de Brum-Fernandes. (2001) Immunohistochemical localization of the prostacyclin receptor (IP) in human bone. Prostagladins Leukot Essent Fatty Acids; 65 (2) 79-83.
  • R Samadfam, C Teixera, G Bkaily, P Sirois, AJ De Brum-Fernandes, and P d’Orleans-Juste. (1999). Significant contribution of the B2 receptor in Arthus reaction-induced estravasatoin in normal or B2 transgenic mice. British Journal of Pharmacology 129 (8) 1732-8.